You are here


05 - 12 - 2017

Zika: a very encouraging Phase I clinical trial

A vaccine against the Zika virus has been tested in phase I. It was well tolerated and resulted in the production of effective antibodies that protected mice from experimental infection.

Zika virus can cause serious birth defects and various health problems in children and adults. Work on the development of a vaccine is ongoing.

A double-blinded phase I study on an inactivated vaccine has just been completed.

The vaccine was well tolerated by the people, and blood samples showed the presence of antibodies against the virus.

These antibodies were isolated and injected into mice which then received the Zika virus. Analysis of the blood samples taken from these animals did not detect the presence of the virus, indicating that the antibodies produced solid immunity.

Encouraged by these results, clinical trials are continuing.